Skip to main content
logo
Veraxa Biotech AG (VRXA)
NASDAQ: VRXA · Real-Time Price · USD
1.200
+0.070 (6.19%)
Oct 30, 2026, 11:51 AM EDT - Market open

Veraxa Biotech AG Cash Flow Statement

Millions CHF. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Net Income
-66.61-28.13-16.54
Depreciation & Amortization
1.971.871.84
Other Amortization
00.010.01
Loss (Gain) From Sale of Assets
0.020.03-
Stock-Based Compensation
52.6618.337.61
Other Operating Activities
0.88-0.260.51
Change in Accounts Payable
0.9-0.12-0.36
Change in Other Net Operating Assets
10.560.53
Operating Cash Flow
-9.9-7.72-7.27
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Capital Expenditures
-0.44-0.12-0.23
Cash Acquisitions
---0.78
Investing Cash Flow
-0.44-0.12-1.02

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Short-Term Debt Issued
1--
Total Debt Issued
1--
Long-Term Debt Repaid
-0.16--
Lease Payments
-0.16--
Net Debt Issued (Repaid)
0.84--
Issuance of Common Stock
5.761.8512.54
Financing Cash Flow
6.591.8512.54

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Net Cash Flow
-3.75-5.994.25

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Free Cash Flow
-10.34-7.84-7.5
Free Cash Flow Growth
---
Free Cash Flow Margin
-44136.89%--
Free Cash Flow Per Share
-0.71-0.56-0.55
Levered Free Cash Flow
15.753.07-
Unlevered Free Cash Flow
15.753.07-
Free Cash Flow After Leases
-10.5-7.84-7.5

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Change in Working Capital
1.180.44-0.69
SEC Filings: 10-K · 10-Q